Infertility medicine issue: Probe report 'against' Ramdev

Image
Press Trust of India Dehradun
Last Updated : Jan 31 2016 | 5:42 PM IST
The inquiry committee, set up by Uttarakhand government to examine the controversial infertility medicine produced by Ramdev's pharmacy, has submitted its report which is "not in favour" of the Yoga Guru.
The state government had formed the three-member committee last year to probe 'Putrajeevak Beej', an ayuvedic product which allegedly promises a male child.
The report has been sent to Uttarakhand Chief Minister Harish Rawat and will be submitted to the Union government after he gives the go ahead, state's Principal Secretary, Health, Om Prakash, said.
"The inquiry report on Putrajeevak medicine is not in favour of Ramdev. The report has been sent to Chief Minister Harish Rawat," Prakash said, while refusing to divulge the details.
The product courted controversy when on May 1, Rajya Sabha MPs led by JD(U)'s K C Tyagi demanded a ban on it and sought stringent action against the manufacturer.
The Centre had then directed the Uttarakhand government to launch an inquiry into the matter.
However, Ramdev had rejected the allegations, saying the medicine helps in curing infertility in women and termed as "false and misleading" reports that it promises a male child.
The committee, which was earlier headed by AYUSH Drug Controller PD Chamoli, however, gave a clean chit to Ramdev, saying that the nomenclature of the drug was in accordance with the ancient Ayurvedic books and literature.
But, after the Chamoli committee report, the state government asked the DG Health and state law department to examine the matter and submit its report, which has turned out against Ramdev, Prakash added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 31 2016 | 5:42 PM IST

Next Story